7 results on '"Strunz, Celia M. C."'
Search Results
2. Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
- Author
-
Strunz, Celia M. C.
- Subjects
FIBRILAÇÃO ATRIAL (TERAPIA) - Published
- 2012
3. Polimorfismo S447X da lipase lipoprotéica: influência sobre a incidência de doença arterial coronariana prematura e sobre os lípides plasmáticos
- Author
-
Almeida, Katia A., Strunz, Celia M. C., Raul Maranhão, and Mansur, Antonio P.
- Subjects
lipoproteins ,Mutações da lípase lipoprotéica ,Lipoprotein lipase mutations ,triglicérides ,cholesterol ,colesterol ,lipoproteínas ,triglycerides - Abstract
OBJETIVO: O objetivo deste estudo foi avaliar o efeito do polimorfismo S447X sobre os lípides plasmáticos em pacientes com doença arterial coronariana (DAC) prematura. MÉTODOS: Os lípides plasmáticos e a genotipagem foram determinados em 2 grupos: 313 pacientes com DAC prematura (
- Published
- 2007
4. Effect of Hypoglycemic Agents on Ischemic Preconditioning in Patients With Type 2 Diabetes and Symptomatic Coronary Artery Disease.
- Author
-
RAHMI, ROSA MARIA, UCHIDA, AUGUSTO HIROSHI, REZENDE, PAULO CURY, LIMA, EDUARDO GOMES, GARZILLO, CIBELE LARROSA, FAVARATO, DESIDERIO, STRUNZ, CELIA M. C., TAKIUTI, MYRTHES, GIRARDI, PRISCYLA, HUEB, WHADY, FILHO, ROBERTO KALIL, and RAMIRES, JOSÉ A. F.
- Subjects
HYPOGLYCEMIC agents ,INSULIN research ,TYPE 2 diabetes ,DIABETES ,CORONARY disease - Abstract
OBJECTIVE - To assess the effect of two hypoglycemic drugs on ischemic preconditioning d (IPC) patients with type 2 diabetes and coronary artery disease (CAD). RESEARCH DESIGN ANDMETHODS We performed a prospective study of 96 consecutive patients allocated into two groups: 42 to group repaglinide (R) and 54 to group vildagliptin (V). All patients underwent two consecutive exercise tests (ET1 and ET2) in phase 1 without drugs. In phase 2, 1 day after ET1 and -2, 2 mg repaglinide three times daily or 50 mg vildagliptin twice daily was given orally to patients in the respective group for 6 days. On the seventh day, 60 min after 6 mg repaglinide or 100 mg vildagliptin, all patients underwent two consecutive exercise tests (ET3 and ET4). RESULTS In phase 1, IPC was demonstrated by improvement in the time to 1.0 mm ST-segment depression and rate pressure product (RPP). All patients developed ischemia in ET3; however, 83.3% of patients in group R experienced ischemia earlier in ET4, without significant improvement in RPP, indicating the cessation of IPC (P < 0.0001). In group V, only 28% of patients demonstrated IPC cessation, with 72% still having the protective effect (P < 0.0069). CONCLUSIONS Repaglinide eliminated myocardial IPC, probably by its effect on the K
ATP channel. Vildagliptin did not damage this protective mechanismin a relevant way in patients with type 2 diabetes and CAD, suggesting a good alternative treatment in this population. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
5. Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization.
- Author
-
Nakashima CAK, Dallan LAO, Lisboa LAF, Jatene FB, Hajjar LA, Soeiro AM, Furtado RHM, Dalçoquio TF, Baracioli LM, Lima FG, Giraldez RRCV, Silva BA, Costa MSS, Strunz CMC, Dallan LRP, Barbosa CJDG, Britto FAB, Farkouh ME, Gurbel PA, and Nicolau JC
- Subjects
- Acute Coronary Syndrome economics, Acute Coronary Syndrome surgery, Aged, Aspirin administration & dosage, Aspirin adverse effects, Blood Transfusion statistics & numerical data, Female, Hospital Costs statistics & numerical data, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors administration & dosage, Platelet Aggregation Inhibitors adverse effects, Postoperative Hemorrhage chemically induced, Postoperative Hemorrhage prevention & control, Preoperative Care instrumentation, Purinergic P2Y Receptor Antagonists adverse effects, Acute Coronary Syndrome drug therapy, Blood Coagulation Tests instrumentation, Coronary Artery Bypass statistics & numerical data, Purinergic P2Y Receptor Antagonists administration & dosage, Time-to-Treatment statistics & numerical data
- Abstract
Background: Dual antiplatelet therapy is recommended for patients with acute coronary syndromes (ACS). Approximately 10% to 15% of these patients will undergo coronary artery bypass graft (CABG) surgery for index events, and current guidelines recommend stopping clopidogrel at least 5 days before CABG. This waiting time has clinical and economic implications., Objectives: This study aimed to evaluate if a platelet reactivity-based strategy is noninferior to standard of care for 24-h post-CABG bleeding., Methods: In this randomized, open label noninferiority trial, 190 patients admitted with ACS with indications for CABG and on aspirin and P2Y
12 receptor inhibitors, were assigned to either control group, P2Y12 receptor inhibitor withdrawn 5 to 7 days before CABG, or intervention group, daily measurements of platelet reactivity by Multiplate analyzer (Roche Diagnostics GmbH, Vienna, Austria) with CABG planned the next working day after platelet reactivity normalization (pre-defined as ≥46 aggregation units)., Results: Within the first 24 h of CABG, the median chest tube drainage was 350 ml (interquartile range [IQR]: 250 to 475 ml) and 350 ml (IQR: 255 to 500 ml) in the intervention and control groups, respectively (p for noninferiority <0.001). The median waiting period between the decision to undergo CABG and the procedure was 112 h (IQR: 66 to 142 h) and 136 h (IQR: 112 to 161 h) (p < 0.001), respectively. In the intention-to-treat analysis, a 6.4% decrease in the median in-hospital expenses was observed in the intervention group (p = 0.014), with 11.2% decrease in the analysis per protocol (p = 0.003)., Conclusions: A strategy based on platelet reactivity-guided is noninferior to the standard of care in patients with ACS awaiting CABG regarding peri-operative bleeding, significantly shortens the waiting time to CABG, and decreases hospital expenses. (Evaluation of Platelet Aggregability in the Release of CABG in Patients With ACS With DAPT; NCT02516267)., Competing Interests: Funding Support and Author Disclosures This study was financed in part by the Coordination for the Improvement of Higher Education Personnel-Brazil (CAPES) – Finance Code 001. Dr. Furtado has received grants and personal fees from AstraZeneca; personal fees from Servier; and grants from EMS, Pfizer, Novo Nordisk, DalCor, Novartis, and Janssen, all outside the submitted work. Dr. Baracioli has received personal fees from Sandoz. Dr. Barbosa has received personal fees from Bayer, Daiichi-Sankyo, and Servier. Dr. Britto has received research grants from Novo Nordisk, DalCor, AstraZeneca, and Novartis. Dr. Farkouh has received research grants from Amgen, Novartis, and Novo Nordisk. Dr. Gurbel has received consultant and/or receives honoraria from Bayer, Merck, Janssen, Medicure, and USWorld Meds; has received grants from the National Institutes of Health, Janssen, Merck, Bayer, Haemonetics, Instrumentation Labs, and Amgen; holds stock or stock options in Merck, Medtronic, and Pfizer; and holds patents in the area of personalized antiplatelet therapy and interventional cardiology. Dr. Nicolau has received personal fees from AMGEN; has received grants from AstraZeneca, Bristol Myers Squibb, CLS Behring, Dalcor, Janssen, NovoNordisk, and Vifor; has received grants and personal fees from Bayer, Novartis, and Sanofi; and has received personal fees from Daiichi-Sankyo and Servier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
6. Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation.
- Author
-
Mansur Ade P, Takada JY, Avakian SD, and Strunz CM
- Subjects
- Age Factors, Aged, Aged, 80 and over, Chi-Square Distribution, Chronic Disease, Female, Humans, International Normalized Ratio, Male, Reference Values, Time Factors, Treatment Outcome, Anticoagulants administration & dosage, Atrial Fibrillation blood, Warfarin administration & dosage
- Abstract
Objective: Anticoagulation is a challenge for the prophylaxis of thromboembolic events in elderly patients with chronic atrial fibrillation. Stable anticoagulation is defined as the time within >70% of the therapeutic range. However, the dosage required to achieve stable anticoagulation remains unknown. The aim of this study was to analyze the warfarin dose necessary for the maintenance of stable oral anticoagulation therapy in elderly patients., Methods: We analyzed 112 consecutive outpatients with atrial fibrillation who were >65 years of age, had received anticoagulation therapy with warfarin for more than 1 year and had a stable international normalized ratio between 2.0 and 3.0 for >6 months. The international normalized ratio was measured in the central laboratory using the traditional method., Results: The patients were stratified according to the following age groups: <75 or >75 years and <80 or >80 years. The mean daily doses of warfarin were similar for patients <75 or >75 years (3.34+1.71 versus 3.26 +1.27 mg/ day, p = 0.794) and <80 or >80 years (3.36+ 1.49 versus 3.15 + 1.23 mg/day, p = 0.433). In 88 (79%) patients, the daily warfarin dose was between 2 and 5 mg/day; in 13 (11%) patients, the daily warfarin dose was <2.0 mg/day; and in 11 (10%) patients, the daily warfarin dose was >5.0 mg/day. The correlation between the daily warfarin dose and the international normalized ratio was 0.22 (p = 0.012)., Conclusion: Stable anticoagulation was achieved in 80% of patients who received doses of 2 to 5 mg/day of warfarin, and the mean daily dose was similar across the age groups analyzed.
- Published
- 2012
- Full Text
- View/download PDF
7. Major depressive disorder and inflammatory markers in elderly patients with heart failure.
- Author
-
Andrei AM, Fraguas R Jr, Telles RM, Alves TC, Strunz CM, Nussbacher A, Rays J, Iosifescu DV, and Wajngarten M
- Subjects
- Aged, Biomarkers, Depressive Disorder, Major diagnosis, Diagnostic and Statistical Manual of Mental Disorders, Female, Humans, Male, Prevalence, C-Reactive Protein metabolism, Depressive Disorder, Major blood, Depressive Disorder, Major epidemiology, Heart Failure blood, Heart Failure epidemiology, Interleukin-6 blood, Tumor Necrosis Factor-alpha blood
- Abstract
The authors evaluated levels of inflammatory markers in 34 chronic heart failure (CHF) out-patients age 65 years and over, with (N=18) and without (N=16) major depressive disorder (MDD), and healthy-control subjects (N=13). Patients with CHF had left-ventricular ejection fractions <0.40 and were in the New York Heart Association functional class II or III. The authors used the SCID DSM-IV to diagnosis MDD. High-sensitivity C-reactive protein levels were significantly higher in patients with CHF and MDD as compared with healthy-control subjects. No differences regarding tumor necrosis factor(alpha) or interleukin(6) were found among the three groups.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.